XBiotech (XBIT) Stock Price, News & Analysis

Company Overview

XBiotech, Inc. is a clinical-stage biotechnology company focused on developing therapies based on naturally occurring human antibodies. Its True Human antibody platform is designed to identify and produce antibody-based medicines that replicate immune proteins found in healthy individuals, with the goal of treating inflammatory, oncologic and other serious diseases.

The company’s leading candidate has been bermekimab, a monoclonal antibody that targets interleukin-1 alpha, an inflammatory protein involved in multiple disease processes. XBiotech has evaluated bermekimab in clinical studies for conditions including cancer and inflammatory diseases. The company also develops additional antibody candidates and related technologies intended to support the discovery and manufacture of biologic medicines.

Founded in 2005 and headquartered in Austin, Texas, XBiotech has conducted research and clinical development activities in the United States and internationally through clinical trials and collaborations. John Simard, the company’s founder, has served as its chief executive officer. XBiotech’s products remain in development, and the company does not have a broad portfolio of commercially marketed therapies.

Key Stats

• Today's Range: $2.20 to $2.29
• 50-Day Range: $2.15 to $2.46
• 52-Week Range: $2.09 to $3.44
• Volume: 88,032 shs
• Average Volume: 32,263 shs
• Market Capitalization: $69.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

XBiotech Stock Analysis - MarketRank™

XBiotech scored higher than 27% of companies evaluated by MarketBeat, and ranked 782nd out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

XBiotech has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

XBiotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of XBiotech is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of XBiotech is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

XBiotech has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.55% of the float of XBiotech has been sold short.

Short Interest Ratio / Days to Cover

XBiotech has a short interest ratio ("days to cover") of 9.96.

Change versus previous month

Short interest in XBiotech has recently decreased by 5.49%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

XBiotech does not currently pay a dividend.

Dividend Growth

XBiotech does not have a long track record of dividend growth.

News and Social Media

• Score: 4.5 / 5
• News Sentiment: N/A

News Sentiment

XBiotech has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for XBiotech this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for XBIT on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added XBiotech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, XBiotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.80% of the stock of XBiotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.70% of the stock of XBiotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XBIT
• CIK: 1626878
• Web: www.xbiotech.com
• Phone: (512) 386-2900
• Fax: 512-386-5505
• Employees: 87
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): ($1.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.54 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -31.62%
• Return on Assets: -30.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 33.15
• Quick Ratio: 33.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.60 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 30,490,000
• Free Float: 21,098,000
• Market Cap: $69.82 million
• Optionable: Optionable
• Beta: 0.79